DHODH and multiple sclerosis: We expected the AZA-resistant cells to be more sensitive to the inhibition of DHODH by TFN (drug approved by the FDA and EMA for treatment of relapsing forms of multiple sclerosis [44,45]), as was observed in the study by Imanishi et al. (2017) with respect to the metabolic activity/viability of the cells [46].